GSK commences Phase III clinical trials to develop herpes zoster vaccine for the prevention of shingles
GSK新型带状疱疹疫苗已开始进入III期临床实验。参加这次实验的受试者达到3万人，期间主要检测疫苗安全性以及免疫原性。（GlaxoSmithKline plc's (GSK: News ) herpes zoster vaccine candidate, which contains Antigenics' QS-21 Stimulon adjuvant as a key component, has commenced Phase 3 clinical trials for the prevention of shingles. ）
GlaxoSmithKline confirmed today that the company has commenced the Phase III clinical trials programme of its candidate herpes zoster vaccine currently being developed for the prevention of shingles. The phase III clinical trials will study more than 30,000 patients globally and will evaluate the efficacy, safety and immunogenicity of the candidate vaccine.
‘The commencement of the Phase III programme for our candidate herpes zoster vaccine is a significant milestone’, said Norman Begg, Chief Medical Officer of GSK Biologicals. ‘Shingles is an often debilitating condition for which there are limited treatment and prevention options. That is why progression into late stage development of our herpes zoster vaccine is an important milestone in ongoing efforts to potentially help address an important unmet need’.
About shingles and herpes zoster
Herpes Zoster (HZ) or zoster is commonly known as shingles. It is caused by varicella-zoster virus (VZV). HZ occurs at all ages with an estimated 1 million HZ cases per year in the United States1. The overall incidence of herpes zoster in Europe is approximately 3 per 1000 people per year and more than 10 per 1000 people per year in those aged >80 years2. The incidence of HZ increases with age.作者: zhaox 时间: 2015-11-11 14:09
半拉木匠发表于 2010-8-30 10:26 ：